American Society of Hematology

Latest stories

19h
Business Wire
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII InhibitorsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
Business Wire / Posted 19 hours ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to ACE910 (RG6013,... Read more
2 related stories
1d
TheStreet.com
Sarepta, Biomarin, Spark, RaptorBefore I wrote my last column predicting the approvals of Duchenne muscular dys
Sarepta, Biomarin, Spark, Raptor
TheStreet.com / Posted yesterday
Before I wrote my last column predicting the approvals of Duchenne muscular dystrophy drugs drisapersen and eteplirsen, I spoke to a healthcare investor I've known and respected for a long time. This investor agrees with Tony B. He says the FDA is... Read more
1d
TheStreet.com
Sarepta, Biomarin, Spark, RaptorBefore I wrote my last column predicting the approvals of Duchenne muscular dys
Sarepta, Biomarin, Spark, Raptor
TheStreet.com / Posted yesterday
Before I wrote my last column predicting the approvals of Duchenne muscular dystrophy drugs drisapersen and eteplirsen, I spoke to a healthcare investor I've known and respected for a long time. This investor agrees with Tony B. He says the FDA is... Read more
9d
Business Wire
Nordic Nanovector: Results for the Second Quarter and Half Year 2015OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE:NANO), a company focu
Nordic Nanovector: Results for the Second Quarter and Half Year 2015
Business Wire / Posted 9 days ago
OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE:NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces its results for the second quarter and half year... Read more
11d
Business Wire
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune ThrombocytopeniaSAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Business Wire / Posted 11 days ago
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announces that the FDA has approved an expanded use for Promacta® (eltrombopag), a Novartis product, to include children 1 year of age and older with chronic immune... Read more
14d
TheStreet.com
Celldex, Bluebird, Kite, InovioWhen an insider sells a large block of company stock, an outside investor worri
Celldex, Bluebird, Kite, Inovio
TheStreet.com / Posted 14 days ago
When an insider sells a large block of company stock, an outside investor worries there's something materially negative going on at the company. This bad news, not yet disclosed publicly, might have compelled the insider to sell. Insiders might also... Read more
17d
Los Angeles Times
Kite Pharma acknowledges patient death, says unrelated to cell therapyShares of Kite Pharma Inc. rebounded Monday after the company said the death of
Kite Pharma acknowledges patient death, says unrelated to cell therapy
Los Angeles Times / Posted 17 days ago
Shares of Kite Pharma Inc. rebounded Monday after the company said the death of a clinical trial patient was unrelated to its promising blood cancer treatment. The Santa Monica company held a conference call with analysts to address "a high level of... Read more
18d
Business Wire
Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation ConsolidationBOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announce
Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation
Business Wire / Posted 18 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma (HL) at... Read more
1m
News-Medical-Net
Engineered protein shown effective in patients with severe von Willebrand diseaseThe first protein engineered to help control bleeding episodes in patients with
Engineered protein shown effective in patients with severe von Willebrand disease
News-Medical-Net / Posted a month ago
The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease (vW disease) has been shown to be safe and effective, according to results of a Phase III trial. Study data were published online today in... Read more

People in this news